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Prevention and Control of Influenza:
Part II, Antiviral Agents
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
Summary
These recommendations provide information about two antiviral agents:
amantadine hydrochloride and rimantadine hydrochloride. These recommenda-
tions supersede  MMWR 1992;41(No. RR-9). The primary changes include
information about the recently licensed drug rimantadine, expanded informa-
tion on the potential for adverse reactions to amantadine and rimantadine, and
guidelines for the use of these drugs among certain persons.
INTRODUCTION
The two antiviral agents with specific activity against influenza A viruses are aman-
tadine hydrochloride and rimantadine hydrochloride. These chemically related drugs
interfere with the replication cycle of type A (but not type B) influenza viruses. When
administered prophylactically to healthy adults or children before and throughout the
epidemic period, both drugs are approximately 70%–90% effective in preventing
illness caused by naturally occurring strains of type A influenza viruses. Because an-
tiviral agents taken prophylactically may prevent illness but not subclinical infection,
some persons who take these drugs may still develop immune responses that will
protect them when they are exposed to antigenically related viruses in later years.
In otherwise healthy adults, amantadine and rimantadine can reduce the severity
and duration of signs and symptoms of influenza A illness when administered within
48 hours of illness onset. Studies evaluating the efficacy of treatment for children with
either amantadine or rimantadine are limited. Amantadine was approved for treat-
ment and prophylaxis of all influenza type A virus infections in 1976. Although few
placebo-controlled studies were conducted to determine the efficacy of amantadine
treatment among children prior to approval, amantadine is indicated for treatment
and prophylaxis of adults and children ≥1 year of age. Rimantadine was approved in
1993 for treatment and prophylaxis in adults but was approved only for prophylaxis in
children. Further studies may provide the data needed to support future approval of
rimantadine treatment in this age group.
As with all drugs, amantadine and rimantadine may cause adverse reactions in
some persons. Such adverse reactions are rarely severe; however, for some catego-
ries of patients, severe adverse reactions are more likely to occur. Amantadine has
been associated with a higher incidence of adverse central nervous system (CNS)
reactions than rimantadine (see Considerations for Selecting Amantadine or Riman-
tadine for Chemoprophylaxis or Treatment).
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RECOMMENDATIONS FOR THE USE OF AMANTADINE
AND RIMANTADINE
Use as Prophylaxis
Chemoprophylaxis is not a substitute for vaccination. Recommendations for
chemoprophylaxis are provided primarily to help health-care providers make deci-
sions regarding persons who are at greatest risk of severe illness and complications if
infected with influenza A virus (i.e., persons at high risk). Groups at high risk for
influenza-related complications include:
• persons ≥65 years of age;
• residents of nursing homes and other chronic-care facilities that house persons of
any age with chronic medical conditions;
• adults and children with chronic disorders of the pulmonary or cardiovascular sys-
tems, including children with asthma;
• adults and children who have required regular medical follow-up or hospitalization
during the preceding year because of chronic metabolic diseases (including
diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression
(including immunosuppression caused by medications); and
• children and teenagers (6 months–18 years of age) who are receiving long-term
aspirin therapy and therefore may be at risk for developing Reye syndrome after
influenza.
When amantadine or rimantadine is administered as prophylaxis, factors such as
cost, compliance, and potential side effects should be considered when determining
the period of prophylaxis. To be maximally effective as prophylaxis, the drug must be
taken each day for the duration of influenza activity in the community. However, to be
most cost effective, amantadine or rimantadine prophylaxis should be taken only dur-
ing the period of peak influenza activity in a community.
Persons at High Risk Vaccinated After Influenza A Activity Has Begun
Persons at high risk can still be vaccinated after an outbreak of influenza A has
begun in a community. However, the development of antibodies in adults after vacci-
nation can take as long as 2 weeks, during which time chemoprophylaxis should be
considered. Children who receive influenza vaccine for the first time may require as
long as 6 weeks of prophylaxis (i.e., prophylaxis for 2 weeks after the second dose of
vaccine has been received). Amantadine and rimantadine do not interfere with the
antibody response to the vaccine.
Persons Providing Care to Those at High Risk
To reduce the spread of virus to persons at high risk, chemoprophylaxis may be
considered during community outbreaks for a) unvaccinated persons who have fre-
quent contact with persons at high risk (e.g., household members, visiting nurses, and
volunteer workers) and b) unvaccinated employees of hospitals, clinics, and chronic-
care facilities. For those persons who cannot be vaccinated, chemoprophylaxis during
the period of peak influenza activity may be considered. For those persons who
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receive vaccine at a time when influenza A is present in the community, chemopro-
phylaxis can be administered for 2 weeks after vaccination. Prophylaxis should be
considered for all employees, regardless of their vaccination status, if the outbreak is
caused by a variant strain of influenza A that may not be controlled by the vaccine.
Persons Who Have Immune Deficiency
Chemoprophylaxis may be indicated for persons at high risk who are expected to
have an inadequate antibody response to influenza vaccine. This category includes
persons with human immunodeficiency virus (HIV) infection, especially those with ad-
vanced HIV disease. No data are available on possible interactions with other drugs
used in the management of patients with HIV infection. Such patients should be moni-
tored closely if amantadine or rimantadine chemoprophylaxis is administered.
Persons for Whom Influenza Vaccine Is Contraindicated
Chemoprophylaxis throughout the influenza season or during peak influenza activ-
ity may be appropriate for persons at high risk who should not be vaccinated.
Influenza vaccine may be contraindicated in persons with severe anaphylactic hy-
persensitivity to egg protein or other vaccine components.
Other Persons
Amantadine or rimantadine also can be administered prophylactically to anyone
who wishes to avoid influenza A illness. The health-care provider and patient should
make this decision on an individual basis.
Use of Antivirals as Therapy
Amantadine and rimantadine can reduce the severity and shorten the duration of
influenza A illness among healthy adults when administered within 48 hours of illness
onset. Whether antiviral therapy will prevent complications of influenza type A among
high-risk persons is unknown. Insufficient data exist to determine the efficacy of
rimantadine treatment in children. Thus, rimantadine is currently approved only for
prophylaxis in children, but it is not approved for treatment in this age group.
Amantadine- and rimantadine-resistant influenza A viruses can emerge when
either of these drugs is administered for treatment; amantadine-resistant strains are
cross-resistant to rimantadine and vice versa. Both the frequency with which resistant
viruses emerge and the extent of their transmission are unknown, but data indicate
that amantadine- and rimantadine-resistant viruses are no more virulent or transmis-
sible than amantadine- and rimantadine-sensitive viruses. 
The screening of naturally occurring epidemic strains of influenza type A has rarely
detected amantadine- and rimantadine-resistant viruses. Resistant viruses have most
frequently been isolated from persons taking one of these drugs as therapy for influ-
enza A infection. Resistant viruses have been isolated from persons who live at home
or in an institution where other residents are taking or have recently taken amantadine
or rimantadine as therapy. Persons who have influenza-like illness should avoid con-
tact with uninfected persons as much as possible, regardless of whether they are
being treated with amantadine or rimantadine. Persons who have influenza type A
infection and who are treated with either drug may shed amantadine- or rimantadine-
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sensitive viruses early in the course of treatment, but may later shed drug-resistant
viruses, especially after 5–7 days of therapy. Such persons can benefit from therapy
even when resistant viruses emerge; however, they also can transmit infection to
other persons with whom they come in contact. Because of possible induction of
amantadine or rimantadine resistance, treatment of persons who have influenza-like
illness should be discontinued as soon as clinically warranted, generally after 3–5 days
of treatment or within 24–48 hours after the disappearance of signs and symptoms.
Laboratory isolation of influenza viruses obtained from persons who are receiving
amantadine or rimantadine should be reported to CDC through state health depart-
ments, and the isolates should be saved for antiviral sensitivity testing.
Outbreak Control in Institutions
When confirmed or suspected outbreaks of influenza A occur in institutions that
house persons at high risk, chemoprophylaxis should be started as early as possible
to reduce the spread of the virus. Contingency planning is needed to ensure rapid
administration of amantadine or rimantadine to residents. This planning should in-
clude preapproved medication orders or plans to obtain physicians’ orders on short
notice. When amantadine or rimantadine is used for outbreak control, the drug should
be administered to all residents of the institution—regardless of whether they re-
ceived influenza vaccine the previous fall. The drug should be continued for at least
2 weeks or until approximately 1 week after the end of the outbreak. The dose for each
resident should be determined after consulting the dosage recommendations and pre-
cautions (see Considerations for Selecting Amantadine or Rimantadine for
Chemoprophylaxis or Treatment) and the manufacturer’s package insert. To reduce
the spread of virus and to minimize disruption of patient care, chemoprophylaxis also
can be offered to unvaccinated staff who provide care to persons at high risk. Prophy-
laxis should be considered for all employees, regardless of their vaccination status, if
the outbreak is caused by a variant strain of influenza A that is not controlled by the
vaccine.
Chemoprophylaxis also may be considered for controlling influenza A outbreaks in
other closed or semi-closed settings (e.g., dormitories or other settings where persons
live in close proximity). To reduce the spread of infection and the chances of prophy-
laxis failure due to transmission of drug-resistant virus, measures should be taken to
reduce contact as much as possible between persons on chemoprophylaxis and those
taking drug for treatment. 
CONSIDERATIONS FOR SELECTING AMANTADINE
OR RIMANTADINE FOR CHEMOPROPHYLAXIS
OR TREATMENT
Side Effects/Toxicity
Despite the similarities between the two drugs, amantadine and rimantadine differ
in their pharmacokinetic properties. More than 90% of amantadine is excreted
unchanged, whereas approximately 75% of rimantadine is metabolized by the liver.
However, both drugs and their metabolites are excreted by the kidney.
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The pharmacokinetic differences between amantadine and rimantadine may par-
tially explain differences in side effects. Although both drugs can cause CNS and
gastrointestinal side effects when administered to young, healthy adults at equivalent
dosages of 200 mg/day, the incidence of CNS side effects (e.g., nervousness, anxiety,
difficulty concentrating, and lightheadedness) is higher among persons taking aman-
tadine compared with those taking rimantadine. In a 6-week study of prophylaxis in
healthy adults, approximately 6% of participants taking rimantadine at a dose of
200 mg/day experienced at least one CNS symptom, compared with approximately
14% of those taking the same dose of amantadine and 4% of those taking placebo. The
incidence of gastrointestinal side effects (e.g., nausea and anorexia) is approximately
3% in persons taking either drug, compared with 1%–2% of persons receiving the pla-
cebo. Side effects associated with both drugs are usually mild and cease soon after
discontinuing the drug. Side effects may diminish or disappear after the first week
despite continued drug ingestion. However, serious side effects have been observed
(e.g., marked behavioral changes, delirium, hallucinations, agitation, and seizures).
These more severe side effects have been associated with high plasma drug concen-
trations and have been observed most often among persons who have renal
insufficiency, seizure disorders, or certain psychiatric disorders and among elderly
persons who have been taking amantadine as prophylaxis at a dose of 200 mg/day.
Clinical observations and studies have indicated that lowering the dosage of aman-
tadine among these persons reduces the incidence and severity of such side effects,
and recommendations for reduced dosages for these groups of patients have been
made. Because rimantadine has only recently been approved for marketing, its safety
in certain patient populations (e.g., chronically ill and elderly persons) has been evalu-
ated less frequently. Clinical trials of rimantadine have more commonly involved
young, healthy persons. 
Providers should review the package insert before using amantadine or riman-
tadine for any patient. The patient’s age, weight, renal function, other medications,
presence of other medical conditions, and indications for use of amantadine or riman-
tadine (prophylaxis or therapy) must be considered, and the dosage and duration of
treatment must be adjusted appropriately. Modifications in dosage may be required
for persons who have impaired renal or hepatic function, the elderly, children, and
persons with a history of seizures. The following are guidelines for the use of aman-
tadine and rimantadine in certain patient populations. Dosage recommendations are
also summarized (Table 1).
Persons Who Have Impaired Renal Function
Amantadine
 Amantadine is excreted unchanged in the urine by glomerular filtration and tubu-
lar secretion. Thus, renal clearance of amantadine is reduced substantially in persons
with renal insufficiency. A reduction in dosage is recommended for patients with
creatinine clearance ≤50 mL/min. Guidelines for amantadine dosage based on creat-
inine clearance are found in the packet insert. However, because recommended
dosages based on creatinine clearance may provide only an approximation of the
optimal dose for a given patient, such persons should be observed carefully so that
adverse reactions can be recognized promptly and either the dose can be further
Vol. 43 / No. RR-15 MMWR 5
reduced or the drug can be discontinued, if necessary. Hemodialysis contributes little
to drug clearance.
Rimantadine
 The safety and pharmacokinetics of rimantadine among patients with renal insuf-
ficiency have been evaluated only after single-dose administration. Further studies are
needed to determine the multiple-dose pharmacokinetics and the most appropriate
dosages for these patients.
In a single-dose study of patients with anuric renal failure, the apparent clearance
of rimantadine was approximately 40% lower, and the elimination half-life was
approximately 1.6-fold greater than that in healthy controls of the same age. Hemodia-
lysis did not contribute to drug clearance. In studies among persons with less severe
renal disease, drug clearance was also reduced, and plasma concentrations were




1–9 yrs 10–13 yrs 14–64 yrs ≥65 years
Amantadine*
 Treatment 5 mg/kg/day








 Prophylaxis 5 mg/kg/day









 Treatment NA NA 100 mg
twice daily
100 or 200** mg/day
 Prophylaxis 5 mg/kg/day







100 or 200** mg/day
NOTE: Amantadine manufacturers include: Dupont Pharma (Symmetrel

—syrup); Solvay
Pharmaceuticals (Symadine—capsule); Chase Pharmaceuticals and Invamed (Amantadine
HCL—capsule). Rimantadine is manufactured by Forest Laboratories (Flumandine—tablet and
syrup).
 *The drug package insert should be consulted for dosage recommendations for administering
amantadine to persons with creatinine clearance ≤50 mL/min.
 † 5 mg/kg of amantadine or rimantadine syrup = 1 tsp/22 lbs.
 § Children ≥10 years of age who weigh <40 kg should be administered amantadine or
rimantadine at a dose of 5 mg/kg/day.
 ¶ A reduction in dose to 100 mg/day of rimantadine is recommended for persons who have
severe hepatic dysfunction or those with creatinine clearance ≤10 mL/min. Other persons
with less severe hepatic or renal dysfunction taking >100 mg/day should be observed closely,
and the dosage should be reduced or the drug discontinued, if necessary.
**Elderly nursing-home residents should be administered only 100 mg/day of rimantadine. A
reduction in dose to 100 mg/day should be considered for all persons ≥65 years of age if
they experience possible side effects when taking 200 mg/day.
NA=Not applicable.
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higher compared with control patients without renal disease who were the same
weight, age, and sex.
A reduction in dosage to 100 mg/day is recommended for persons with creatinine
clearance ≤10 mL/min. Because of the potential for accumulation of rimantadine and
its metabolites, patients with any degree of renal insufficiency, including elderly
persons, should be monitored for adverse effects, and either the dosage should be
reduced or the drug should be discontinued, if necessary. 
Persons ≥65 Years of Age
Amantadine
Because renal function declines with increasing age, the daily dose for persons
≥65 years of age should not exceed 100 mg for prophylaxis or treatment. For some
elderly persons, the dose should be further reduced. Studies suggest that because of
their smaller average body size, elderly women are more likely than elderly men to
experience side effects at a daily dose of 100 mg.
Rimantadine
The incidence and severity of CNS side effects among elderly persons appear to be
substantially lower among those taking rimantadine at a dose of 200 mg/day com-
pared with elderly persons taking the same dose of amantadine. However, when
rimantadine has been administered at a dosage of 200 mg/day to chronically ill elderly
persons, they have had a higher incidence of CNS and gastrointestinal symptoms
than healthy, younger persons taking rimantadine at the same dosage. After long-
term administration of rimantadine at a dosage of 200 mg/day, serum rimantadine
concentrations among elderly nursing-home residents have been two to four times
greater than those reported in younger adults.
The dosage of rimantadine should be reduced to 100 mg/day for treatment or pro-
phylaxis of elderly nursing-home residents. Although further studies are needed to
determine the optimal dose for other elderly persons, a reduction in dosage to
100 mg/day should be considered for all persons ≥65 years of age if they experience
signs and symptoms that may represent side effects when taking a dosage of
200 mg/day.
Persons Who Have Liver Disease
Amantadine
No increase in adverse reactions to amantadine has been observed among persons
with liver disease.
Rimantadine
The safety and pharmacokinetics of rimantadine have only been evaluated after
single-dose administration. In a study of persons with chronic liver disease (most with
stabilized cirrhosis), no alterations were observed after a single dose. However, in per-
sons with severe liver dysfunction, the apparent clearance of rimantadine was 50%
lower than that reported for persons without liver disease. A dose reduction to
100 mg/day is recommended for persons with severe hepatic dysfunction.
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Persons Who Have Seizure Disorders
Amantadine
An increased incidence of seizures has been reported in patients with a history of
seizure disorders who have received amantadine. Patients with seizure disorders
should be observed closely for possible increased seizure activity when taking
amantadine.
Rimantadine
In clinical trials, seizures (or seizure-like activity) have been observed in a few per-
sons with a history of seizures who were not receiving anticonvulsant medication
while taking rimantadine. The extent to which rimantadine may increase the incidence
of seizures among persons with seizure disorders has not been adequately evaluated,




The use of amantadine in children <1 year of age has not been adequately evalu-
ated. The FDA-approved dosage for children 1–9 years of age is 4.4–8.8 mg/kg/day, not
to exceed 150 mg/day. Although further studies to determine the optimal dosage for
children are needed, physicians should consider prescribing only 5 mg/kg/day (not to
exceed 150 mg/day) to reduce the risk for toxicity. The approved dosage for children
≥10 years of age is 200 mg/day; however, for children weighing <40 kg, prescribing
5 mg/kg/day, regardless of age, is advisable. 
Rimantadine
The use of rimantadine in children <1 year of age has not been adequately evalu-
ated. In children 1–9 years of age, rimantadine should be administered in one or two
divided doses at a dosage of 5 mg/kg/day, not to exceed 150 mg/day. The approved
dosage for children ≥10 years of age is 200 mg/day (100 mg twice a day); however, for




Careful observation is advised when amantadine is administered concurrently with
drugs that affect the CNS, especially CNS stimulants.
Rimantadine
No clinically significant drug interactions have been identified. For more detailed
information concerning potential drug interactions for either drug, the package insert
should be consulted.
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SOURCES OF INFORMATION ON INFLUENZA-CONTROL
PROGRAMS
Information regarding influenza surveillance is available through the CDC Voice In-
formation System (influenza update), telephone (404) 332-4551, or through the CDC
Information Service on the Public Health Network electronic bulletin board. From Oc-
tober through May, the information is updated at least every other week. In addition,
periodic updates about influenza are published in the weekly MMWR. State and local
health departments should be consulted regarding availability of influenza vaccine,
access to vaccination programs, and information about state or local influenza activity.
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